tak-079
mAbexperimental
Clinical trial activity
11 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
7
Phase 3
3
Phase 4
0
Earliest trial started Aug 1, 2014 (NCT02219256)
Timeline
Indications
Mechanism of action
- Lymphocyte differentiation antigen CD38BINDING AGENT
Lymphocyte differentiation antigen CD38 binding agent
- Lymphocyte differentiation antigen CD38Supplementation
CD38 supplementation
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297833 ↗
Also known as
- tak-079
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06948318 | Phase 3 | Aug 14, 2025 | Takeda |
| NCT06963827 | Phase 3 | Jul 15, 2025 | Takeda |
| NCT06722235 | Phase 3 | Feb 10, 2025 | Takeda |
| NCT05174221 | Phase 1 | Nov 9, 2022 | Takeda |
| NCT04776018 | Phase 1/Phase 2 (Phase 2) | Apr 20, 2021 | Takeda |
| NCT04278924 | Phase 2 | Apr 1, 2020 | Millennium Pharmaceuticals |
| NCT04159805 | Phase 2 | Nov 25, 2019 | Takeda |
| NCT03984097 | Phase 1 | Jun 24, 2019 | Millennium Pharmaceuticals |
| NCT03724916 | Phase 1 | Nov 26, 2018 | Millennium Pharmaceuticals |
| NCT03439280 | Phase 1/Phase 2 (Phase 2) | Apr 26, 2018 | Millennium Pharmaceuticals, Takeda |
| NCT02219256 | Phase 1 | Aug 1, 2014 | Takeda |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Takeda | For profit | 8 | 7 | 3 | 2014 |
| Millennium Pharmaceuticals | For profit | 4 | 4 | 2 | 2018 |
2 organizations
Page 1 / 1